## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.6% below STRENGTH zone (4.0-10.0%); PEG 6.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (54% of avg), momentum weakening (-8.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($377.68)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Mackenzie Financial Corp Purchases 96,506 Shares of Waters Corporation $WAT**
- Source: MarketBeat | 20251201T033814 | Bullish | Relevance: 99%
- Mackenzie Financial Corp significantly increased its stake in Waters Corporation (NYSE:WAT) during the second quarter, purchasing 96,506 additional shares to reach a total of 206,670 shares valued at approximately $72.14 million. Waters Corporation, a medical instruments supplier, currently holds an average analyst rating of "Moderate Buy" with a target price of $381.57. The company demonstrates strong profitability and trades with a market capitalization of $24.02 billion.

**2. Morgan Stanley initiates Waters Corp stock coverage with Equalweight rating By Investing.com**
- Source: Investing.com Nigeria | 20251202T161800 | Neutral | Relevance: 99%
- Morgan Stanley has initiated coverage on Waters Corp. (NYSE:WAT) with an Equalweight rating and a price target of $423.00, acknowledging the company's strong financial performance and recurring business model. Despite its operational efficiency and expansion into high-growth areas, concerns exist regarding the integration challenges and "nearer-term uncertainty" following its announced acquisition of Becton Dickinson’s Biosciences and Diagnostics businesses. The stock currently trades at a high P/E ratio, and analysts have revised earnings downwards for the upcoming period.

**3. Morgan Stanley initiates Waters Corp stock coverage with Equalweight rating By Investing.com**
- Source: Investing.com South Africa | 20251202T171800 | Neutral | Relevance: 98%
- Morgan Stanley initiated coverage on Waters Corp. (NYSE:WAT) with an Equalweight rating and a price target of $423.00, citing its strong financial performance and recurring business model. Despite concerns about the integration of recent acquisitions, the company has shown revenue growth and expanding into high-growth areas. Waters Corporation also reported strong Q3 2025 financial results, exceeding analyst expectations for EPS and revenue.

**4. Morgan Stanley initiates Waters Corp stock coverage with Equalweight rating By Investing.com**
- Source: Investing.com UK | 20251202T151800 | Neutral | Relevance: 98%
- Morgan Stanley initiated coverage on Waters Corp. (NYSE:WAT) with an Equalweight rating and a price target of $423.00, citing the company's strong financial performance and recurring business model. Despite positive aspects like expansion into high-growth areas, concerns exist regarding the acquisition of Becton Dickinson’s Biosciences and Diagnostics businesses due to potential integration challenges and "nearer-term uncertainty." The stock is currently trading at a high P/E ratio of 36.7, reflecting a premium valuation.

**5. Morgan Stanley initiates Waters Corp stock coverage with Equalweight rating**
- Source: Investing.com | 20251202T101700 | Neutral | Relevance: 98%
- Morgan Stanley initiated coverage on Waters Corp. (NYSE:WAT) with an Equalweight rating and a price target of $423.00, citing the company's strong financial performance and recurring business model. Despite its operational strengths and growth in new segments, concerns were raised regarding the acquisition of Becton Dickinson’s Biosciences and Diagnostics businesses, which could introduce "nearer-term uncertainty" and integration challenges. The investment bank noted that while the standalone business is favorable, these challenges could limit near-term visibility, aligning with analyst revisions and a high P/E ratio for Waters.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wolfe Research | $48 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wolfe Research | up | Outperform |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 6.42 signals overvaluation risk, limited margin of safety. Forward P/E 27.9x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.6B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.42 |
| Forward P/E | 27.9 |
| Current P/E | 30.4 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 10.4% to 1.6% (-8.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.4pp (needs >4.0% for momentum thesis). MRS_5 (-2.0%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.4% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). Volume at 54% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.57% (CS: 75) | Neutral |
| RSI_14 | 66.1 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.133x | Above |
| vs SMA200 | 1.177x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $398.62
- **Stop Loss:** $377.68 (5.3% risk)
- **Target:** $419.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 47
- **Position Value:** $18,735.14
- **Portfolio %:** 18.74%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*